Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Topical and Rectal Quetiapine vs Oral in Healthy Adults
NCT02131545Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quetiapine (extended-release tablet, brand name: Bipresso) in Dementia and delirium, sponsored by Mayo Clinic. Primary endpoints: Serum quetiapine levels after topical application at 8 hours, Serum quetiapine levels after oral administration at 8 hours and 1 more. Started Jun 2014; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
Dementiadelirium
Beyond the preview
Go deeper on NCT02131545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131545.